Further, we compared percentage of circulating neutrophils, lymphocytes and CLL cells (as assessed by CD5+/CD19+) in patient subgroups according to the disease activity, treatment history and IGHV gene mutational status. The gene discussed is CD5; the disease is B-cell chronic lymphocytic leukemia.